Cost issues in new disease-modifying treatments for advanced cancer: In-depth interviews with physicians

European Journal of Cancer

Volumn 43, Issue 13, 2007, Pages 1983-1989

  de Kort, Susanne J ^a   Kenny, Nuala ^b   van Dijk, Paul ^c   Gevers, Sjef ^d   Richel, Dick J ^d   Willems, Dick L ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Agis Health Insurance   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cost analysis; Ethics; Metastatic cancer; Qualitative research

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER THERAPY; COST BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL CARE; HUMAN; INTERVIEW; MEDICAL ETHICS; NETHERLANDS; ONCOLOGY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; DECISION MAKING; HEALTH CARE COSTS; HUMANS; INTERVIEWS AS TOPIC; MEDICAL ONCOLOGY; NEOPLASMS; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 34548083941     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.05.017     Document Type: Article

References (31)

1. Angell M. The doctor as double agent. Kennedy Inst Ethics J 3 (1993) 279-286
2. Mechanic D. The functions and limitations of trust in the provision of medical care. J Health Polit Policy Law 23 (1998) 661-686
3. Daniels N., and Sabin J.E. Setting limits fairly: can we learn to share medical resources? (2002), Oxford University Press, Oxford
4. Kenny N.P. What good is health care? Reflections on the Canadian experience (2002), CHA Press, Ottawa
5. Minogue B. The two fundamental duties of the physician. Acad Med 75 (2000) 431-442
6. Morreim E.H. Balancing act: the new medical ethics of medicine's new economics (1991), Kluwer Academic Publishers, Boston
7. Reagan M.D. Physicians as gatekeepers. A complex challenge. N Engl J Med 317 (1987) 1731-1734
8. Eddy D.M. Clinical decision making: from theory to practice. Three battles to watch in the 1990s. JAMA 270 (1993) 520-526
9. Tunis S.R. Why Medicare has not established criteria for coverage decisions. N Engl J Med 350 (2004) 2196-2198
10. American Society of Clinical Oncology. Can society afford state-of-the-art cancer oncology treatment? ASCO Annual Meeting; 2005.
11. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351 (2004) 317-319
12. Uyl-de Groot C.A., and Giaccone G. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?. Curr Opin Oncol 17 (2005) 392-396
13. Earle C.C., Neville B.A., Landrum M.B., et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22 (2004) 315-321
14. Emanuel E.J., Young-Xu Y., Levinsky N.G., et al. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138 (2003) 639-643
15. Menzel P., Gold M.R., Nord E., et al. Toward a broader view of values in cost-effectiveness analysis of health. Hastings Cent Rep 29 (1999) 7-15
16. Britten N. Qualitative interviews in medical research. In: Mays N., and Pope C. (Eds). Qualitative research in health care (1996), BMJ Books, London 28-35
17. Eisenhardt K.M. Building theories from case study research. Acad Manage Rev 14 (1989) 532-550
18. Breast Cancer Society [Undertreatment of metastatic HER2-positive breastcancer.] Utrecht; 2005.
19. Jefford M., Savulescu J., Thomson J., et al. Medical paternalism and expensive unsubsidised drugs. BMJ 331 (2005) 1075-1077
20. Thomson J., Schofield P., Mileshkin L., et al. Do oncologists discuss expensive anti-cancer drugs with their patients?. Ann Oncol 17 (2006) 702-708
21. van Delden J.J., Vrakking A.M., van der H.A., and van der Maas P.J. Medical decision making in scarcity situations. J Med Ethics 30 (2004) 207-211
22. Marcus R. Should you tell patients about beneficial treatments that they cannot have? Yes. BMJ 334 (2007) 826
23. Firth J. Should you tell patients about beneficial treatments that they cannot have? No. BMJ 334 (2007) 827
24. Schrag D., and Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 25 (2007) 233-237
25. Wouters M.W., Timmermans D.R., and Kievit J. [Financial limits to care; a survey among physicians]. Ned Tijdschr Geneeskd 141 (1997) 206-210
26. Ministry of Welfare, Health, and Cultural Affairs. [Choices in health care: a report by the government committee on choices in health care.] Rijswijk, The Netherlands; 1992.
27. Devlin N., and Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13 (2004) 437-452
28. Gevers S. Legal issues in the development and use of clinical practice guidelines. Med Law 20 (2001) 183-191
29. Saarni S.I., and Gylling H.A. Evidence based medicine guidelines: a solution to rationing or politics disguised as science?. J Med Ethics 30 (2004) 171-175
30. The goals of medicine. Setting new priorities. Hastings Cent Rep 1996;26:S1-27.
31. de Kort S.J., Willemse P.H., Habraken J.M., et al. Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: a review of randomized controlled clinical trials. Eur J Cancer 42 (2006) 835-845